An Evaluation of the Potential for VH4011499 Drug-drug-interactions
A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants
The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Estude backup de contato
- Nome: EU GSK Clinical Trials Call Center
- Número de telefone: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form (ICF).
-
Male or female:
-
Male Participants:
No restrictions for male participants.
-
A female participant (female sex assigned at birth) is eligible to participate if:
-
They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of contraception since, to be eligible, they must be of nonchildbearing potential.
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
- Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
- Capable of giving signed informed consent.
Exclusion Criteria:
- History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
- Pre-existing clinically relevant, gastro-intestinal pathology or diagnosis.
- A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
- Clinically significant abnormal blood pressure at Screening.
- Lymphoma, leukemia, or any malignancy within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
- Breast cancer within the past 10 years.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
- History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long QT syndrome.
- History of seizure(s) and / or other clinically significant neurological conditions.
- Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
- Participants with any history of any drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
- Participant is mentally or legally incapacitated.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
- Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
- Unable to refrain from the use of prescription or non-prescription medications.
- Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
- Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
- Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
- Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
- Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
- Current enrollment or past participation in this clinical study.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- eGFR <90 mL/min or serum creatinine >1.1× upper limit of normal (ULN) .
- Hemoglobin <12.5 g/dL for men and <11 g/dL for women.
- Participants with active hepatitis B virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
- Positive Hepatitis C antibody test result at Screening.
- Positive pre-study drug/alcohol screen.
- Positive HIV-1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium <135 millimole/L.
- Regular alcohol consumption within 6 months prior to Screening.
- Regular use of known drugs of abuse.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
- Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
- Prior exposure to VH4011499 or Lenacapavir in any formulation..
- Study participants with ALT >1.0x ULN or total bilirubin >1.5x ULN are excluded at Screening.
- Any significant arrhythmia or ECG findings meeting protocol-defined exclusion criteria.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Cohort 1: VH4011499 + Ritonavir
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir. |
VH4011499 is administered to the participants based on the protocol schedule. Ritonavir is administered to the participants based on the protocol schedule. |
|
Experimental: Cohort 2: VH4011499 + Efavirenz
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz. |
VH4011499 is administered to the participants based on the protocol schedule. Efavirenz is administered to the participants based on the protocol schedule. |
|
Experimental: Cohort 3: VH4011499 + Carbamazepine
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose. |
VH4011499 is administered to the participants based on the protocol schedule. Carbamazepine is administered to the participants based on the protocol schedule. |
|
Experimental: Cohort 4: VH4011499 + Metformin + Digoxin
Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499. |
VH4011499 is administered to the participants based on the protocol schedule. Metformin is administered to the participants based on the protocol schedule. Digoxin is administered to the participants based on the protocol schedule. |
|
Experimental: Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin
Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499. |
VH4011499 is administered to the participants based on the protocol schedule. Rosuvastatin is administered to the participants based on the protocol schedule. Pitavastatin is administered to the participants based on the protocol schedule. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
Prazo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
Cmax of VH4011499 when co-administered with Ritonavir
Prazo: Day 26
|
Day 26
|
|
Cmax of VH4011499 when co-administered with Efavirenz
Prazo: Day 37
|
Day 37
|
|
Cmax of VH4011499 when co-administered with Carbamazepine
Prazo: Day 41
|
Day 41
|
|
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
Prazo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
AUC(0-t) of VH4011499 when co-administered with Ritonavir
Prazo: Day 26
|
Day 26
|
|
AUC(0-t) of VH4011499 when co-administered with Efavirenz
Prazo: Day 37
|
Day 37
|
|
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
Prazo: Day 41
|
Day 41
|
|
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
Prazo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
Prazo: Day 26
|
Day 26
|
|
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
Prazo: Day 37
|
Day 37
|
|
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
Prazo: Day 41
|
Day 41
|
|
Cmax of Metformin when administered alone
Prazo: Day 1
|
Day 1
|
|
Cmax of Metformin when co-administered with VH4011499
Prazo: Day 16
|
Day 16
|
|
AUC(0-t) of Metformin when administered alone
Prazo: Day 1
|
Day 1
|
|
AUC(0-t) of Metformin when co-administered with VH4011499
Prazo: Day 16
|
Day 16
|
|
AUC(0-inf) of Metformin when administered alone
Prazo: Day 1
|
Day 1
|
|
AUC(0-inf) of Metformin when co-administered with VH4011499
Prazo: Day 16
|
Day 16
|
|
Cmax of Digoxin when administered alone
Prazo: Day 1
|
Day 1
|
|
Cmax of Digoxin when co-administered with VH4011499
Prazo: Day 16
|
Day 16
|
|
AUC(0-t) of Digoxin when administered alone
Prazo: Day 1
|
Day 1
|
|
AUC(0-t) of Digoxin when co-administered with VH4011499
Prazo: Day 16
|
Day 16
|
|
AUC(0-inf) of Digoxin when administered alone
Prazo: Day 1
|
Day 1
|
|
AUC(0-inf) of Digoxin when co-administered with VH4011499
Prazo: Day 16
|
Day 16
|
|
Cmax of Rosuvastatin when administered alone
Prazo: Day 5
|
Day 5
|
|
Cmax of Rosuvastatin when co-administered with VH4011499
Prazo: Day 22
|
Day 22
|
|
AUC(0-t) of Rosuvastatin when administered alone
Prazo: Day 5
|
Day 5
|
|
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
Prazo: Day 22
|
Day 22
|
|
AUC(0-inf) of Rosuvastatin when administered alone
Prazo: Day 5
|
Day 5
|
|
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
Prazo: Day 22
|
Day 22
|
|
Cmax of Pitavastatin when administered alone
Prazo: Day 1
|
Day 1
|
|
Cmax of Pitavastatin when co-administered with VH4011499
Prazo: Day 17
|
Day 17
|
|
AUC(0-t) of Pitavastatin when administered alone
Prazo: Day 1
|
Day 1
|
|
AUC(0-t) of Pitavastatin when co-administered with VH4011499
Prazo: Day 17
|
Day 17
|
|
AUC(0-inf) of Pitavastatin when administered alone
Prazo: Day 1
|
Day 1
|
|
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
Prazo: Day 17
|
Day 17
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with adverse events (AEs), overall and by grade.
Prazo: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death. |
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
Number of participants with AEs leading to study treatment discontinuation
Prazo: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
|
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Prazo: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
|
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Prazo: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death. |
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
Prazo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
Tmax of VH4011499 when co-administered with Ritonavir
Prazo: Day 26
|
Day 26
|
|
|
Tmax of VH4011499 when co-administered with Efavirenz
Prazo: Day 37
|
Day 37
|
|
|
Tmax of VH4011499 when co-administered with Carbamazepine
Prazo: Day 41
|
Day 41
|
|
|
Apparent oral clearance (CL/F) of VH4011499 when administered alone
Prazo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
CL/F of VH4011499 when co-administered with Ritonavir
Prazo: Day 26
|
Day 26
|
|
|
CL/F of VH4011499 when co-administered with Efavirenz
Prazo: Day 37
|
Day 37
|
|
|
CL/F of VH4011499 when co-administered with Carbamazepine
Prazo: Day 41
|
Day 41
|
|
|
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
Prazo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
t1/2 of VH4011499 when co-administered with Ritonavir
Prazo: Day 26
|
Day 26
|
|
|
t1/2 of VH4011499 when co-administered with Efavirenz
Prazo: Day 37
|
Day 37
|
|
|
t1/2 of VH4011499 when co-administered with Carbamazepine
Prazo: Day 41
|
Day 41
|
|
|
Cmax of VH4011499 when co-administered with Metformin and Digoxin
Prazo: Day 16
|
Day 16
|
|
|
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
Prazo: Day 16
|
Day 16
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
Prazo: Day 16
|
Day 16
|
|
|
Cmax of Ritonavir when co-administered with VH4011499
Prazo: Day 26
|
Day 26
|
|
|
AUC(0-t) of Ritonavir when co-administered with VH4011499
Prazo: Day 26
|
Day 26
|
|
|
AUC(0-inf) of Ritonavir when co-administered with VH4011499
Prazo: Day 26
|
Day 26
|
|
|
Cmax of Efavirenz when co-administered with VH4011499
Prazo: Day 37
|
Day 37
|
|
|
AUC(0-t) of Efavirenz when co-administered with VH4011499
Prazo: Day 37
|
Day 37
|
|
|
AUC(0-inf) of Efavirenz when co-administered with VH4011499
Prazo: Day 37
|
Day 37
|
|
|
Cmax of Carbamazepine when co-administered with VH4011499
Prazo: Day 41
|
Day 41
|
|
|
AUC(0-t) of Carbamazepine when co-administered with VH4011499
Prazo: Day 41
|
Day 41
|
|
|
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
Prazo: Day 41
|
Day 41
|
|
|
Cmax of VH4011499 when co-administered with Rosuvastatin
Prazo: Day 22
|
Day 22
|
|
|
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
Prazo: Day 22
|
Day 22
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
Prazo: Day 22
|
Day 22
|
|
|
Cmax of VH4011499 when co-administered with Pitavastatin
Prazo: Day 17
|
Day 17
|
|
|
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
Prazo: Day 17
|
Day 17
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
Prazo: Day 17
|
Day 17
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções transmitidas pelo sangue
- Doenças urogenitais
- Doenças Genitais
- Doenças do sistema imunológico
- Infecções
- Infecções por vírus de RNA
- Doenças Virais
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Síndromes de Deficiência Imunológica
- Doenças de Vírus Lento
- Infecções por HIV
- Síndrome da Imunodeficiência Adquirida
- Compostos de enxofre
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, anel fundido
- Tiazóis
- Azoles
- Hidrocarbonetos
- Carboidratos
- Compostos policíclicos
- Glicosídeos
- Amidas
- Pirimidinas
- Esteróides
- Compostos de anel fundido
- Hidrocarbonetos, halogenados
- Biguanides
- Guanidinas
- Amidines
- Sulfonamidas
- Sulfonas
- Dibenzazepínicos
- Compostos heterocíclicos, 3 anel
- Fluorobenzenos
- Hidrocarbonetos, fluorados
- Digitalis glicosídeos
- Cardenolides
- Glicosídeos cardíacos
- Cardanolídeos
- Rosuvastatina Cálcio
- Digoxina
- Metformina
- Ritonavir
- Carbamazepina
- Efavirenz
- Pitavastatina
Outros números de identificação do estudo
Outros números de identificação do estudo
- 309014
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf
Prazo de Compartilhamento de IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Critérios de acesso de compartilhamento IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .